Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654842 | 0.86 | PTGDR2 (0.54) | PTGDR2KMT2AMEN1BRD4 | |
| SCHEMBL5390308 | 0.85 | PTGDR2 (0.53) | PTGDR2KMT2AMEN1BRD4 | |
| SCHEMBL586210 | 0.83 | PTGDR2 (0.74) | PTGDR2 | |
| SCHEMBL1651608 | 0.83 | PTGDR2 (0.51) | PTGDR2KMT2ABRD4 | |
| SCHEMBL1333614 | 0.82 | PTGS2 (0.53) | PTGDR2KMT2AMEN1PTGS2SMN1; SMN2 | |
| SCHEMBL11649824 | 0.80 | FFAR1 (0.55) | PTGDR2KMT2AMEN1PTGS2SMN1; SMN2 | |
| SCHEMBL585902 | 0.79 | PTGDR2 (0.57) | PTGDR2KMT2ABRD4 | |
| SCHEMBL1332131 | 0.79 | PTGDR2 (0.55) | PTGDR2KMT2ABRD4HCRTR1HCRTR2 | |
| SCHEMBL2396297 | 0.79 | PTGDR2 (0.57) | PTGDR2KMT2ABRD4 | |
| SCHEMBL8168262 | 0.78 | PTGDR2 (0.53) | PTGDR2KMT2APTGS2HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1963259-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | AstraZeneca AB (SE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068894-A2 | SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293775-A1 | Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease | PNMT, SQOR, SMS | PTGDR2 120/4885KMT2A 1651/4885MEN1 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.